Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $21 from $19 and keeps an Outperform rating on the shares ahead of the Q1 report. The firm reduced Amylyx’s spending assumptions to reflect the company’s current pipeline and timelines. It remains bullish on Amylyx’s lead asset, avexitide and sees a favorable risk/reward at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
- Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
- Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
- Amylyx price target raised to $30 from $25 at Guggenheim
- Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program